The sickle cell disease treatment market is experiencing significant expansion, driven by increasing disease awareness, rising prevalence, and breakthrough therapies from key pharmaceutical players, ...

CRISPR Therapeutics (NASDAQ:CRSP) has delayed a much-anticipated Phase 1 trial readout for CTX320, its in vivo gene editing ...

CRISPR Therapeutics CRSP and Intellia Therapeutics NTLA are leading developers of therapies that utilize the Nobel ...

Changing how biopharmas package their products, how regulators review new drugs and how mutated genes are fixed could make ...

CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for ...

We spoke with the developers and manufacturers of the CRISPR gene therapy used to treat KJ Muldoon’s rare genetic condition, ...

Crispr investors have had a year to put aside so far, with the stock down 25%. Read more on CRSP's execution risks, high ...

A recent study involving researchers from the University of Basel reveals that slowing down the intracellular transport of ...

Repositioning genes awakens fetal hemoglobin to treat disease. CRISPR editing may change future gene therapy. Researchers ...

Baby KJ Muldoon, the first patient to successfully receive personalized CRISPR gene editing therapy has returned home after over 300 days at the hospital.

Back in 1900 the life expectancy of people with Down Syndrome was 9 years. In 1984, it was 28 years, today it's leveled off ...